Amicus Therapeutics Stock Z Score

FOLD Stock

USD 9.96 0.09 0.91%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Amicus Therapeutics Piotroski F Score and Amicus Therapeutics Valuation analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

At present, Amicus Therapeutics' Long Term Debt To Capitalization is projected to increase slightly based on the last few years of reporting. The current year's Total Debt To Capitalization is expected to grow to 0.75, whereas Capital Lease Obligations is forecasted to decline to about 44.3 M. At present, Amicus Therapeutics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 496.5 M, whereas EBIT is forecasted to decline to (104.9 M).

Amicus Therapeutics Company Z Score Analysis

Amicus Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Amicus Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Amicus Therapeutics is extremely important. It helps to project a fair market value of Amicus Stock properly, considering its historical fundamentals such as Z Score. Since Amicus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Amicus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Amicus Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Retained Earnings	Total Liab	Accounts Payable	Short Term Investments	Common Stock	Property Plant Equipment	Net Debt	Long Term Debt	Total Current Assets	Short Term Debt	Current Deferred Revenue	Net Tangible Assets	Net Receivables	Good Will	Capital Surpluse	Deferred Long Term Liab	Intangible Assets	Long Term Debt Total	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.85	-0.61	0.88	0.49	0.63	0.72	0.59	0.49	0.63	0.84	0.51	0.53	-0.34	0.36	0.95	0.7	0.41	0.49	0.67	0.01	0.84	0.52	0.44	0.43
Total Stockholder Equity	0.85		-0.34	0.59	0.7	0.79	0.52	0.44	0.24	0.34	0.73	0.3	0.4	-0.03	0.07	0.79	0.44	0.38	0.42	0.34	0.12	0.69	0.52	0.51	0.15
Retained Earnings	-0.61	-0.34		-0.78	-0.25	-0.29	-0.97	-0.89	-0.88	-0.95	-0.8	-0.42	0.09	0.04	-0.94	-0.74	-0.94	0.31	0.22	-0.92	0.53	-0.8	-0.4	-0.26	-0.94
Total Liab	0.88	0.59	-0.78		0.26	0.33	0.84	0.67	0.64	0.81	0.75	0.61	0.51	-0.52	0.66	0.9	0.75	0.32	0.41	0.77	-0.38	0.79	0.32	0.24	0.66
Accounts Payable	0.49	0.7	-0.25	0.26		0.63	0.37	0.41	0.17	0.19	0.53	0.0	0.04	0.29	0.08	0.44	0.33	0.03	0.06	0.19	0.08	0.47	0.5	0.49	0.14
Short Term Investments	0.63	0.79	-0.29	0.33	0.63		0.42	0.34	0.47	0.38	0.76	0.06	-0.06	0.37	-0.01	0.6	0.41	-0.04	-0.01	0.42	0.35	0.63	0.74	0.76	0.05
Common Stock	0.72	0.52	-0.97	0.84	0.37	0.42		0.9	0.83	0.92	0.86	0.45	0.01	-0.05	0.86	0.83	0.93	-0.18	-0.09	0.88	-0.47	0.84	0.44	0.32	0.88
Property Plant Equipment	0.59	0.44	-0.89	0.67	0.41	0.34	0.9		0.71	0.8	0.79	0.34	-0.12	0.14	0.81	0.65	0.86	-0.31	-0.23	0.76	-0.37	0.72	0.56	0.42	0.92
Net Debt	0.49	0.24	-0.88	0.64	0.17	0.47	0.83	0.71		0.94	0.78	0.3	-0.26	0.11	0.8	0.65	0.83	-0.44	-0.37	0.92	-0.32	0.75	0.5	0.42	0.75
Long Term Debt	0.63	0.34	-0.95	0.81	0.19	0.38	0.92	0.8	0.94		0.83	0.36	-0.05	-0.09	0.87	0.75	0.88	-0.27	-0.18	0.96	-0.47	0.82	0.48	0.39	0.83
Total Current Assets	0.84	0.73	-0.8	0.75	0.53	0.76	0.86	0.79	0.78	0.83		0.28	0.01	0.12	0.57	0.87	0.88	-0.13	-0.05	0.87	-0.07	0.94	0.76	0.66	0.63
Short Term Debt	0.51	0.3	-0.42	0.61	0.0	0.06	0.45	0.34	0.3	0.36	0.28		0.49	-0.54	0.39	0.53	0.38	0.41	0.43	0.33	-0.26	0.2	0.09	0.03	0.4
Current Deferred Revenue	0.53	0.4	0.09	0.51	0.04	-0.06	0.01	-0.12	-0.26	-0.05	0.01	0.49		-0.87	-0.15	0.4	-0.09	0.95	0.96	-0.07	0.0	0.13	-0.2	-0.18	-0.15
Net Tangible Assets	-0.34	-0.03	0.04	-0.52	0.29	0.37	-0.05	0.14	0.11	-0.09	0.12	-0.54	-0.87		-0.09	-0.28	0.04	-0.78	-0.8	-0.05	0.25	-0.03	0.43	0.43	-0.02
Net Receivables	0.36	0.07	-0.94	0.66	0.08	-0.01	0.86	0.81	0.8	0.87	0.57	0.39	-0.15	-0.09		0.54	0.81	-0.39	-0.32	0.8	-0.72	0.6	0.2	0.08	0.95
Good Will	0.95	0.79	-0.74	0.9	0.44	0.6	0.83	0.65	0.65	0.75	0.87	0.53	0.4	-0.28	0.54		0.79	0.24	0.32	0.77	-0.18	0.92	0.44	0.35	0.55
Capital Surpluse	0.7	0.44	-0.94	0.75	0.33	0.41	0.93	0.86	0.83	0.88	0.88	0.38	-0.09	0.04	0.81	0.79		-0.27	-0.18	0.94	-0.28	0.86	0.53	0.36	0.86
Deferred Long Term Liab	0.41	0.38	0.31	0.32	0.03	-0.04	-0.18	-0.31	-0.44	-0.27	-0.13	0.41	0.95	-0.78	-0.39	0.24	-0.27		0.99	-0.27	0.18	-0.05	-0.24	-0.19	-0.37
Intangible Assets	0.49	0.42	0.22	0.41	0.06	-0.01	-0.09	-0.23	-0.37	-0.18	-0.05	0.43	0.96	-0.8	-0.32	0.32	-0.18	0.99		-0.18	0.14	0.03	-0.21	-0.17	-0.29
Long Term Debt Total	0.67	0.34	-0.92	0.77	0.19	0.42	0.88	0.76	0.92	0.96	0.87	0.33	-0.07	-0.05	0.8	0.77	0.94	-0.27	-0.18		-0.29	0.86	0.56	0.43	0.79
Long Term Investments	0.01	0.12	0.53	-0.38	0.08	0.35	-0.47	-0.37	-0.32	-0.47	-0.07	-0.26	0.0	0.25	-0.72	-0.18	-0.28	0.18	0.14	-0.29		-0.15	0.27	0.26	-0.55
Short Long Term Debt	0.84	0.69	-0.8	0.79	0.47	0.63	0.84	0.72	0.75	0.82	0.94	0.2	0.13	-0.03	0.6	0.92	0.86	-0.05	0.03	0.86	-0.15		0.53	0.43	0.61
Net Invested Capital	0.52	0.52	-0.4	0.32	0.5	0.74	0.44	0.56	0.5	0.48	0.76	0.09	-0.2	0.43	0.2	0.44	0.53	-0.24	-0.21	0.56	0.27	0.53		0.97	0.33
Net Working Capital	0.44	0.51	-0.26	0.24	0.49	0.76	0.32	0.42	0.42	0.39	0.66	0.03	-0.18	0.43	0.08	0.35	0.36	-0.19	-0.17	0.43	0.26	0.43	0.97		0.16
Capital Stock	0.43	0.15	-0.94	0.66	0.14	0.05	0.88	0.92	0.75	0.83	0.63	0.4	-0.15	-0.02	0.95	0.55	0.86	-0.37	-0.29	0.79	-0.55	0.61	0.33	0.16

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Amicus Therapeutics

According to the company's disclosures, Amicus Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

Amicus Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Amicus Therapeutics from analyzing Amicus Therapeutics' financial statements. These drivers represent accounts that assess Amicus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Amicus Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	2.3B	6.0B	3.1B	3.5B	4.2B	4.4B
Enterprise Value	2.4B	6.3B	3.3B	3.8B	4.4B	4.6B

Amicus Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Amicus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Amicus Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Amicus Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Amicus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Amicus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Amicus Therapeutics' value.

		Shares
Palo Alto Investors, Llc	2024-09-30	8.1 M
Macquarie Group Ltd	2024-06-30	7.1 M
Geode Capital Management, Llc	2024-09-30	6.6 M
Fiera Capital Corporation	2024-06-30	5.3 M
Pictet Asset Manangement Sa	2024-06-30	4.2 M
American Century Companies Inc	2024-09-30	3.9 M
Citadel Advisors Llc	2024-09-30	3.6 M
Northern Trust Corp	2024-09-30	3.2 M
Massachusetts Financial Services Company	2024-09-30	3.2 M
Vanguard Group Inc	2024-09-30	28.8 M
Perceptive Advisors Llc	2024-09-30	28.1 M

Amicus Fundamentals

	Return On Equity	-0.67
	Return On Asset	0.0116
	Profit Margin	(0.21) %
	Operating Margin	0.18 %
	Current Valuation	3.17 B
	Shares Outstanding	298.81 M
	Shares Owned By Insiders	0.73 %
	Shares Owned By Institutions	99.27 %
	Number Of Shares Shorted	21 M
	Price To Earning	(9.18) X
	Price To Book	16.64 X
	Price To Sales	6.03 X
	Revenue	399.36 M
	Gross Profit	290.63 M
	EBITDA	(92.08 M)
	Net Income	(151.58 M)
	Cash And Equivalents	386.84 M
	Cash Per Share	1.38 X
	Total Debt	445.06 M
	Debt To Equity	2.60 %
	Current Ratio	3.02 X
	Book Value Per Share	0.60 X
	Cash Flow From Operations	(69.09 M)
	Short Ratio	7.28 X
	Earnings Per Share	(0.34) X
	Price To Earnings To Growth	(0.18) X
	Target Price	17.75
	Number Of Employees	500
	Beta	0.67
	Market Capitalization	2.98 B
	Total Asset	777.88 M
	Retained Earnings	(2.68 B)
	Working Capital	315.37 M
	Current Asset	216.6 M
	Current Liabilities	73.62 M
	Net Asset	777.88 M

About Amicus Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Amicus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amicus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amicus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:

How To Invest In Amicus

Details

Is Amicus Stock a good investment?

Details

What is Amicus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Amicus Therapeutics Piotroski F Score and Amicus Therapeutics Valuation analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.34)

Revenue Per Share

1.629

Quarterly Revenue Growth

0.367

Return On Assets

0.0116

Return On Equity

(0.67)

The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amicus Therapeutics Stock Z Score

Amicus Therapeutics Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Amicus Z Score Driver Correlations

Amicus Therapeutics Current Valuation Drivers

Amicus Therapeutics ESG Sustainability

Amicus Therapeutics Institutional Holders

Amicus Fundamentals

About Amicus Therapeutics Fundamental Analysis

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY